Host |
Rabbit |
Klon |
BC5 |
Format |
Ready-to-use |
Methode |
P |
Vorbehandlung |
Citrate |
Positivkontrolle |
Tonsil |
Verdünnung |
- |
Isotyp |
Rabbit IgG |
Lokalisation |
Nucleus, cytoplasm |
MUM-1 Protein
|
Biocare Medical |
BC5 |
6 ml |
Ready-to-use |
CE/IVD |
PRM352AA |
-
|
Host |
Rabbit |
Klon |
SP114 |
Reaktivität |
BV,CK,DG,MS,RB,RT |
Methode |
IHC-P, WB |
Verdünnung |
1:100 |
MUM1 / IRF4
|
Zytomed Systems GmbH |
SP114 |
0.5 ml |
- |
RUO |
513-4142 |
-
|
Host |
Rabbit |
Klon |
SP114 |
Format |
Concentrate |
Methode |
P, WB |
Vorbehandlung |
EDTA |
Positivkontrolle |
Hodgkin´s Lymphoma |
Verdünnung |
1:100 |
Isotyp |
Rabbit IgG |
Verdünnung |
Synthetic peptide near C-terminus of human MUM1/IRF4 |
Lokalisation |
Nucleus |
MUM1 / IRF4
|
Zytomed Systems GmbH |
SP114 |
1 ml |
Concentrate |
RUO |
513-4144 |
-
|
Host |
Rabbit |
Klon |
polyclonal |
Format |
Purified |
Methode |
P |
Positivkontrolle |
infected tissue |
Isotyp |
Rabbit IgG |
Verdünnung |
Purified PPD from M. tuberculosis |
Mycobacterium tuberculosis
|
Zytomed Systems GmbH |
polyclonal |
1 ml |
Purified |
RUO |
613-0282 |
-
|
Host |
Rabbit |
Klon |
polyclonal |
Format |
Concentrate |
Methode |
P |
Vorbehandlung |
- |
Positivkontrolle |
Tubercolosis infected lung |
Verdünnung |
1:500 - 1:1000 |
Isotyp |
not determined |
Lokalisation |
Bacterial rods and byproducts |
Mycobacterium tuberculosis
|
Biocare Medical |
polyclonal |
0.1 ml |
Concentrate |
CE/IVD |
ACI140A |
-
|
Host |
Rabbit |
Klon |
polyclonal |
Format |
Concentrate |
Methode |
P |
Vorbehandlung |
- |
Positivkontrolle |
Tubercolosis infected lung |
Verdünnung |
1:500 - 1:1000 |
Isotyp |
not determined |
Lokalisation |
Bacterial rods and byproducts |
Mycobacterium tuberculosis
|
Biocare Medical |
polyclonal |
1 ml |
Concentrate |
CE/IVD |
ACI140C |
-
|
Host |
Rabbit |
Klon |
polyclonal |
Format |
Ready-to-use |
Methode |
P |
Vorbehandlung |
- |
Positivkontrolle |
Tubercolosis infected lung |
Verdünnung |
- |
Isotyp |
not determined |
Lokalisation |
Bacterial rods and byproducts |
Mycobacterium tuberculosis
|
Biocare Medical |
polyclonal |
6 ml |
Ready-to-use |
CE/IVD |
API140AA |
-
|
Host |
Monospecific Rabbit |
Klon |
ZR109 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Vorbehandlung |
Citrate or EDTA |
Positivkontrolle |
Brain. |
Verdünnung |
1:100 - 1:200 |
Isotyp |
Rabbit IgG |
Verdünnung |
Recombinant fragment (around aa 150-250) of human MBP |
Lokalisation |
Cytoplasm |
Myelin Basic Protein (MBP)
|
Zeta Corporation |
ZR109 |
1 ml |
Concentrate |
CE/IVD |
Z2411RL |
-
|
Host |
Monospecific Rabbit |
Klon |
ZR109 |
Format |
Ready-to-use |
Reaktivität |
- |
Methode |
P |
Vorbehandlung |
Citrate or EDTA |
Positivkontrolle |
Brain. |
Verdünnung |
- |
Isotyp |
Rabbit IgG |
Verdünnung |
Recombinant fragment (around aa 150-250) of human MBP |
Lokalisation |
Cytoplasm |
Myelin Basic Protein (MBP)
|
Zeta Corporation |
ZR109 |
7 ml |
Ready-to-use |
CE/IVD |
Z2411RP |
-
|
Host |
Monospecific Rabbit |
Klon |
ZR109 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Vorbehandlung |
Citrate or EDTA |
Positivkontrolle |
Brain. |
Verdünnung |
1:100 - 1:200 |
Isotyp |
Rabbit IgG |
Verdünnung |
Recombinant fragment (around aa 150-250) of human MBP |
Lokalisation |
Cytoplasm |
Myelin Basic Protein (MBP)
|
Zeta Corporation |
ZR109 |
0.5 ml |
Concentrate |
CE/IVD |
Z2411RS |
-
|
Host |
Monospecific Rabbit |
Klon |
ZR109 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Vorbehandlung |
Citrate or EDTA |
Positivkontrolle |
Brain. |
Verdünnung |
1:100 - 1:200 |
Isotyp |
Rabbit IgG |
Verdünnung |
Recombinant fragment (around aa 150-250) of human MBP |
Lokalisation |
Cytoplasm |
Myelin Basic Protein (MBP)
|
Zeta Corporation |
ZR109 |
0.1 ml |
Concentrate |
CE/IVD |
Z2411RT |
-
|
Host |
Monospecific Mouse |
Klon |
ZM202 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Vorbehandlung |
Citrate or EDTA |
Positivkontrolle |
Brain. |
Verdünnung |
1:100 - 1:200 |
Isotyp |
IgG2a /κ |
Verdünnung |
Recombinant fragment (around aa 150-250) of human MBP |
Lokalisation |
Cytoplasm |
Myelin Basic Protein (MBP)
|
Zeta Corporation |
ZM202 |
1 ml |
Concentrate |
CE/IVD |
Z2485ML |
-
|
Host |
Monospecific Mouse |
Klon |
ZM202 |
Format |
Ready-to-use |
Reaktivität |
- |
Methode |
P |
Vorbehandlung |
Citrate or EDTA |
Positivkontrolle |
Brain. |
Verdünnung |
- |
Isotyp |
IgG2a /κ |
Verdünnung |
Recombinant fragment (around aa 150-250) of human MBP |
Lokalisation |
Cytoplasm |
Myelin Basic Protein (MBP)
|
Zeta Corporation |
ZM202 |
7 ml |
Ready-to-use |
CE/IVD |
Z2485MP |
-
|
Host |
Monospecific Mouse |
Klon |
ZM202 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Vorbehandlung |
Citrate or EDTA |
Positivkontrolle |
Brain. |
Verdünnung |
1:100 - 1:200 |
Isotyp |
IgG2a /κ |
Verdünnung |
Recombinant fragment (around aa 150-250) of human MBP |
Lokalisation |
Cytoplasm |
Myelin Basic Protein (MBP)
|
Zeta Corporation |
ZM202 |
0.5 ml |
Concentrate |
CE/IVD |
Z2485MS |
-
|
Host |
Monospecific Mouse |
Klon |
ZM202 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Vorbehandlung |
Citrate or EDTA |
Positivkontrolle |
Brain. |
Verdünnung |
1:100 - 1:200 |
Isotyp |
IgG2a /κ |
Verdünnung |
Recombinant fragment (around aa 150-250) of human MBP |
Lokalisation |
Cytoplasm |
Myelin Basic Protein (MBP)
|
Zeta Corporation |
ZM202 |
0.1 ml |
Concentrate |
CE/IVD |
Z2485MT |
-
|
Host |
Rabbit |
Klon |
polyclonal |
Format |
Ready-to-use |
Methode |
P |
Vorbehandlung |
N/A |
Positivkontrolle |
Tissue with inflammatory proces (tonsil, colon cancer) |
Verdünnung |
- |
Isotyp |
not determined |
Lokalisation |
Cytoplasmic |
Myeloperoxidase
|
Biocare Medical |
polyclonal |
25 ml |
Ready-to-use |
CE/IVD |
PP023H |
-
|
Host |
Mouse |
Klon |
ZM352 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Spleen, bone marrow |
Verdünnung |
1:100 - 1:200 |
Isotyp |
IgG2b/κ |
Verdünnung |
Recombinant fragment (around aa150-250) of human MPO protein |
Lokalisation |
Cytoplasm |
Myeloperoxidase
|
Zeta Corporation |
ZM352 |
1 ml |
Concentrate |
CE/IVD |
Z2680ML |
-
|
Host |
Mouse |
Klon |
ZM352 |
Format |
Ready-to-use |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Spleen, bone marrow |
Verdünnung |
- |
Isotyp |
IgG2b/κ |
Verdünnung |
Recombinant fragment (around aa150-250) of human MPO protein |
Lokalisation |
Cytoplasm |
Myeloperoxidase
|
Zeta Corporation |
ZM352 |
7 ml |
Ready-to-use |
CE/IVD |
Z2680MP |
-
|
Host |
Mouse |
Klon |
ZM352 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Spleen, bone marrow |
Verdünnung |
1:100 - 1:200 |
Isotyp |
IgG2b/κ |
Verdünnung |
Recombinant fragment (around aa150-250) of human MPO protein |
Lokalisation |
Cytoplasm |
Myeloperoxidase
|
Zeta Corporation |
ZM352 |
0.5 ml |
Concentrate |
CE/IVD |
Z2680MS |
-
|
Host |
Mouse |
Klon |
ZM352 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Spleen, bone marrow |
Verdünnung |
1:100 - 1:200 |
Isotyp |
IgG2b/κ |
Verdünnung |
Recombinant fragment (around aa150-250) of human MPO protein |
Lokalisation |
Cytoplasm |
Myeloperoxidase
|
Zeta Corporation |
ZM352 |
0.1 ml |
Concentrate |
CE/IVD |
Z2680MT |
-
|
Host |
Mouse |
Klon |
2C7 |
Format |
Purified |
Methode |
F, P, EL, WB, FL |
Positivkontrolle |
Bone Marrow |
Verdünnung |
1:500 - 1:1000 (P) |
Isotyp |
Mouse IgG1 |
Verdünnung |
Human myeloperoxidase |
Myeloperoxidase (MPO, pANCA)
|
Zytomed Systems GmbH |
2C7 |
200 µg |
Purified |
RUO |
613-0318 |
-
|
Host |
Mouse |
Klon |
2C7 |
Format |
Purified |
Methode |
F, P, FL |
Positivkontrolle |
Bone Marrow |
Verdünnung |
1:500 - 1:1000 (P) |
Isotyp |
Mouse IgG1 |
Verdünnung |
Human myeloperoxidase |
Myeloperoxidase (MPO, pANCA)
|
Zytomed Systems GmbH |
2C7 |
20 µg |
Purified |
RUO |
613-0319 |
-
|
Host |
Rabbit |
Klon |
SP72 |
Format |
Concentrate |
Methode |
P |
Vorbehandlung |
Citrate |
Positivkontrolle |
Tonsil |
Verdünnung |
1:100 |
Isotyp |
Rabbit IgG |
Verdünnung |
A synthetic peptide corresponding to C-terminus of human myeloperoxidase protein |
Lokalisation |
Cytoplasm |
Myeloperoxidase (MPO)
|
Zytomed Systems GmbH |
SP72 |
0.1 ml |
Concentrate |
RUO |
513-3720 |
-
|
Host |
Mouse |
Klon |
59A5 |
Format |
Concentrate |
Methode |
F, P |
Vorbehandlung |
Citrate |
Positivkontrolle |
Tonsil |
Verdünnung |
1:25 - 1:50 |
Isotyp |
Mouse IgG2b kappa |
Verdünnung |
Recombinant protein corresponding to 101 amino acids from exon 7 of human myeloperoxidase |
Lokalisation |
Cytoplasm |
Myeloperoxidase (MPO)
|
Diagnostic Biosystems |
59A5 |
1 ml |
Concentrate |
CE/IVD |
MOB551 |
-
|
Host |
Mouse |
Klon |
59A5 |
Format |
Concentrate |
Methode |
F, P |
Vorbehandlung |
Citrate |
Positivkontrolle |
Tonsil |
Verdünnung |
1:25 - 1:50 |
Isotyp |
Mouse IgG2b kappa |
Verdünnung |
Recombinant protein corresponding to 101 amino acids from exon 7 of human myeloperoxidase |
Lokalisation |
Cytoplasm |
Myeloperoxidase (MPO)
|
Diagnostic Biosystems |
59A5 |
0.1 ml |
Concentrate |
CE/IVD |
MOB551-01 |
-
|
Host |
Mouse |
Klon |
59A5 |
Format |
Concentrate |
Methode |
F, P |
Vorbehandlung |
Citrate |
Positivkontrolle |
Tonsil |
Verdünnung |
1:25 - 1:50 |
Isotyp |
Mouse IgG2b kappa |
Verdünnung |
Recombinant protein corresponding to 101 amino acids from exon 7 of human myeloperoxidase |
Lokalisation |
Cytoplasm |
Myeloperoxidase (MPO)
|
Diagnostic Biosystems |
59A5 |
0.5 ml |
Concentrate |
CE/IVD |
MOB551-05 |
-
|
Host |
Mouse |
Klon |
59A5 |
Format |
Ready-to-use |
Methode |
F, P |
Vorbehandlung |
Citrate |
Positivkontrolle |
Tonsil |
Verdünnung |
- |
Isotyp |
Mouse IgG2b kappa |
Verdünnung |
Recombinant protein corresponding to 101 amino acids from exon 7 of human myeloperoxidase |
Lokalisation |
Cytoplasm |
Myeloperoxidase (MPO)
|
Diagnostic Biosystems |
59A5 |
6 ml |
Ready-to-use |
CE/IVD |
PDM551 |
-
|
Host |
Rabbit |
Klon |
polyclonal |
Format |
Ready-to-use |
Methode |
F, P |
Vorbehandlung |
Citrate |
Positivkontrolle |
Tonsil |
Verdünnung |
- |
Isotyp |
Rabbit IgG |
Lokalisation |
Cytoplasm |
Myeloperoxidase (MPO)
|
Diagnostic Biosystems |
polyclonal |
6 ml |
Ready-to-use |
CE/IVD |
PDR049 |
-
|
Host |
Rabbit |
Klon |
polyclonal |
Format |
Concentrate |
Methode |
F, P |
Vorbehandlung |
Citrate |
Positivkontrolle |
Tonsil |
Verdünnung |
1:25 - 1:100 |
Isotyp |
Rabbit IgG |
Lokalisation |
Cytoplasm |
Myeloperoxidase (MPO)
|
Diagnostic Biosystems |
polyclonal |
1 ml |
Concentrate |
CE/IVD |
RP053 |
-
|
Host |
Rabbit |
Klon |
polyclonal |
Format |
Concentrate |
Methode |
F, P |
Vorbehandlung |
Citrate |
Positivkontrolle |
Tonsil |
Verdünnung |
1:25 - 1:100 |
Isotyp |
Rabbit IgG |
Lokalisation |
Cytoplasm |
Myeloperoxidase (MPO)
|
Diagnostic Biosystems |
polyclonal |
0.1 ml |
Concentrate |
CE/IVD |
RP053-01 |
-
|
Host |
Rabbit |
Klon |
polyclonal |
Format |
Concentrate |
Methode |
F, P |
Vorbehandlung |
Citrate |
Positivkontrolle |
Tonsil |
Verdünnung |
1:25 - 1:100 |
Isotyp |
Rabbit IgG |
Lokalisation |
Cytoplasm |
Myeloperoxidase (MPO)
|
Diagnostic Biosystems |
polyclonal |
0.5 ml |
Concentrate |
CE/IVD |
RP053-05 |
-
|
Host |
Mouse |
Klon |
5.2F |
Format |
Concentrate |
Methode |
P |
Vorbehandlung |
Citrate |
Positivkontrolle |
Tonsil |
Verdünnung |
1:25 - 1:50 |
Isotyp |
Mouse IgG2a |
Lokalisation |
Nucleus |
MyoD1
|
Diagnostic Biosystems |
5.2F |
1 ml |
Concentrate |
CE/IVD |
MOB278 |
-
|
Host |
Mouse |
Klon |
5.2F |
Format |
Concentrate |
Methode |
P |
Vorbehandlung |
Citrate |
Positivkontrolle |
Tonsil |
Verdünnung |
1:25 - 1:50 |
Isotyp |
Mouse IgG2a |
Lokalisation |
Nucleus |
MyoD1
|
Diagnostic Biosystems |
5.2F |
0.1 ml |
Concentrate |
CE/IVD |
MOB278-01 |
-
|
Host |
Mouse |
Klon |
5.2F |
Format |
Concentrate |
Methode |
P |
Vorbehandlung |
Citrate |
Positivkontrolle |
Tonsil |
Verdünnung |
1:25 - 1:50 |
Isotyp |
Mouse IgG2a |
Lokalisation |
Nucleus |
MyoD1
|
Diagnostic Biosystems |
5.2F |
0.5 ml |
Concentrate |
CE/IVD |
MOB278-05 |
-
|
Host |
Mouse |
Klon |
5.2F |
Format |
Ready-to-use |
Methode |
P |
Vorbehandlung |
Citrate |
Positivkontrolle |
Tonsil |
Verdünnung |
- |
Isotyp |
Mouse IgG2a |
Lokalisation |
Nucleus |
MyoD1
|
Diagnostic Biosystems |
5.2F |
6 ml |
Ready-to-use |
CE/IVD |
PDM120 |
-
|
Host |
Rabbit |
Klon |
ZR262 |
Format |
Concentrate |
Methode |
P |
Positivkontrolle |
Rhabdomyosarcoma |
Verdünnung |
1:100 - 1:200 |
Isotyp |
IgG |
Lokalisation |
Nuclear and cytoplasmic |
MyoD1
|
Zeta Corporation |
ZR262 |
1 ml |
Concentrate |
CE/IVD |
Z2576RL |
-
|
Host |
Rabbit |
Klon |
ZR262 |
Format |
Ready-to-use |
Methode |
P |
Positivkontrolle |
Rhabdomyosarcoma |
Verdünnung |
RTU |
Isotyp |
IgG |
Lokalisation |
Nuclear and cytoplasmic |
MyoD1
|
Zeta Corporation |
ZR262 |
7.0 ml |
Ready-to-use |
CE/IVD |
Z2576RP |
-
|
Host |
Rabbit |
Klon |
ZR262 |
Format |
Concentrate |
Methode |
P |
Positivkontrolle |
Rhabdomyosarcoma |
Verdünnung |
1:100 - 1:200 |
Isotyp |
IgG |
Lokalisation |
Nuclear and cytoplasmic |
MyoD1
|
Zeta Corporation |
ZR262 |
0.5 ml |
Concentrate |
CE/IVD |
Z2576RS |
-
|
Host |
Rabbit |
Klon |
ZR262 |
Format |
Concentrate |
Methode |
P |
Positivkontrolle |
Rhabdomyosarcoma |
Verdünnung |
1:100 - 1:200 |
Isotyp |
IgG |
Lokalisation |
Nuclear and cytoplasmic |
MyoD1
|
Zeta Corporation |
ZR262 |
0.1 ml |
Concentrate |
CE/IVD |
Z2576RT |
-
|
Host |
Mouse |
Klon |
F5D |
Format |
Concentrate |
Methode |
F, P, WB, IP, IF |
Vorbehandlung |
Citrate |
Positivkontrolle |
Rhabdomyosarcoma |
Verdünnung |
1:50 - 1:100 |
Isotyp |
Mouse IgG1 |
Lokalisation |
Nucleus |
Myogenin
|
Diagnostic Biosystems |
F5D |
1 ml |
Concentrate |
CE/IVD |
MOB322 |
-
|
Host |
Mouse |
Klon |
F5D |
Format |
Concentrate |
Methode |
F, P, WB, IP, IF |
Vorbehandlung |
Citrate |
Positivkontrolle |
Rhabdomyosarcoma |
Verdünnung |
1:50 - 1:100 |
Isotyp |
Mouse IgG1 |
Lokalisation |
Nucleus |
Myogenin
|
Diagnostic Biosystems |
F5D |
0.1 ml |
Concentrate |
CE/IVD |
MOB322-01 |
-
|
Host |
Mouse |
Klon |
F5D |
Format |
Concentrate |
Methode |
F, P, WB, IP, IF |
Vorbehandlung |
Citrate |
Positivkontrolle |
Rhabdomyosarcoma |
Verdünnung |
1:50 - 1:100 |
Isotyp |
Mouse IgG1 |
Lokalisation |
Nucleus |
Myogenin
|
Diagnostic Biosystems |
F5D |
0.5 ml |
Concentrate |
CE/IVD |
MOB322-05 |
-
|
Host |
Mouse |
Klon |
F5D |
Format |
Ready-to-use |
Methode |
F, P |
Vorbehandlung |
Citrate |
Positivkontrolle |
Rhabdomyosarcoma |
Verdünnung |
- |
Isotyp |
Mouse IgG1 |
Lokalisation |
Nucleus |
Myogenin
|
Diagnostic Biosystems |
F5D |
6 ml |
Ready-to-use |
CE/IVD |
PDM158 |
-
|
Host |
Mouse |
Klon |
F5D |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Rhabdomyosarcoma. |
Verdünnung |
1:100 - 1:200 |
Isotyp |
IgG1 /κ |
Verdünnung |
Recombinant protein containing rat myogenin aa 30-224 |
Lokalisation |
Nucleus |
Myogenin
|
Zeta Corporation |
F5D |
1ml |
Concentrate |
CE/IVD |
Z2054ML |
-
|
Host |
Mouse |
Klon |
F5D |
Format |
Ready-to-use |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Rhabdomyosarcoma. |
Verdünnung |
- |
Isotyp |
IgG1 /κ |
Verdünnung |
Recombinant protein containing rat myogenin aa 30-224 |
Lokalisation |
Nucleus |
Myogenin
|
Zeta Corporation |
F5D |
7 ml |
Ready-to-use |
CE/IVD |
Z2054MP |
-
|
Host |
Mouse |
Klon |
F5D |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Rhabdomyosarcoma. |
Verdünnung |
1:100 - 1:200 |
Isotyp |
IgG1 /κ |
Verdünnung |
Recombinant protein containing rat myogenin aa 30-224 |
Lokalisation |
Nucleus |
Myogenin
|
Zeta Corporation |
F5D |
0.5 ml |
Concentrate |
CE/IVD |
Z2054MS |
-
|
Host |
Mouse |
Klon |
F5D |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Rhabdomyosarcoma. |
Verdünnung |
1:100 - 1:200 |
Isotyp |
IgG1 /κ |
Verdünnung |
Recombinant protein containing rat myogenin aa 30-224 |
Lokalisation |
Nucleus |
Myogenin
|
Zeta Corporation |
F5D |
0.1 ml |
Concentrate |
CE/IVD |
Z2054MT |
-
|
Host |
Mouse |
Klon |
ZM149 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Rhabdomyosarcoma or Wilm's tumor. |
Verdünnung |
1:100 - 1:200 |
Isotyp |
IgG1 /κ |
Verdünnung |
Human myogenin recombinant protein |
Lokalisation |
Nucleus |
Myogenin
|
Zeta Corporation |
ZM149 |
1.0 ml |
Concentrate |
CE/IVD |
Z2462ML |
-
|
Host |
Mouse |
Klon |
ZM149 |
Format |
Ready-to-use |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Rhabdomyosarcoma or Wilm's tumor. |
Verdünnung |
- |
Isotyp |
IgG1 /κ |
Verdünnung |
Human myogenin recombinant protein |
Lokalisation |
Nucleus |
Myogenin
|
Zeta Corporation |
ZM149 |
7 ml |
Ready-to-use |
CE/IVD |
Z2462MP |
-
|
Host |
Mouse |
Klon |
ZM149 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Rhabdomyosarcoma or Wilm's tumor. |
Verdünnung |
1:100 - 1:200 |
Isotyp |
IgG1 /κ |
Verdünnung |
Human myogenin recombinant protein |
Lokalisation |
Nucleus |
Myogenin
|
Zeta Corporation |
ZM149 |
0.5 ml |
Concentrate |
CE/IVD |
Z2462MS |
-
|